Retifanlimab (Zynyz)
Canadian Journal of Health Technologies · 19.11.2026 · 6 (11)
DOI: 10.51731/cjht.2026.1571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 19.11.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Retifanlimab (Zynyz), 500 mg/20 mL (25 mg/mL), concentrate for solution, IV infusion. Indication: In combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent SCAC.
Zitieren
APA
CDA-AMC (2026). Retifanlimab (Zynyz). Canadian Journal of Health Technologies, 6(11). https://doi.org/10.51731/cjht.2026.1571
Vancouver
CDA-AMC. Retifanlimab (Zynyz). Canadian Journal of Health Technologies. 2026;6(11). doi:10.51731/cjht.2026.1571
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Retifanlimab (Zynyz)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {11},
doi = {10.51731/cjht.2026.1571}
}
EUVIMED